BY MARKETWIRE
-
J&J’s sales of Darzalex beat expectations
In line with estimates gathered by Bloomberg Information, gross sales of USD 2.94bn had been anticipated.
-
Jefferies: Lundbeck acquisition larger than expected in both size and potential
The monetary solutions firm sees Lundbeck’s assumptions for peak sales of USD 1.5-2bn as greater than anticipated.
-
Novo Nordisk: Catalent acquisition has been misunderstood
Legislator Elizabeth Warren desires an examination right into Novo Nordisk’s USD 11bn purchase of Catalent manufacturing facilities.
-
Lundbeck sees potential for double blockbuster sales from Longboard asset
The cost for the American biotech business is not established expensive, states Charl Van Zyl.
-
Demant gains market share for sales to US veterans – GN dips slightly
Swiss Sonova, the globe’s biggest listening devices producer, shed market share.
-
16 new obesity drugs could be launched by 2029, analysis predicts
Novo Nordisk and Eli Lilly are anticipated to be able to safeguard their market shares to a huge degree, nonetheless, states United States economic solutions strong Morningstar.
-
Novo Nordisk clinches vital obesity data as bank analysts foresee success
In Stage 2 tests, Novo Nordisk’s medication prospect Cagrisema has actually currently shown weight management of even more 15% after 32 weeks.
-
Novo Holdings’ acquisition of Catalent raises concerns as senator seeks to overturn deal
The procurement can provide Novo Nordisk an unlawful benefit in the weight-loss medication market, saysUS Legislator Elizabeth Warren.
-
Another FDA delay for Zealand Pharma as partner factory continues to cause problems
Zealand Pharma’s companion manufacturing facility has not yet formally been okayed adhering to FDA evaluations in August and September.
-
Regeneron founder warns against negative effects of weight loss drugs
George Yancopoulos, founder of Regeneron, thinks that the quick muscle mass loss of present excessive weight medications is very dangerous to people. Regeneron itself is servicing …
